Picture of Black Diamond Therapeutics logo

BDTX Black Diamond Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Momentum

Relative Strength (%)
1m-4.09%
3m-32.55%
6m+35.3%
1yr-59.74%
Volume Change (%)
10d/3m-48.51%
Price vs... (%)
52w High-66.3%
50d MA+13.02%
200d MA-17.15%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-60.94%
Return on Equity-54.49%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Black Diamond Therapeutics EPS forecast chart

Profile Summary

Black Diamond Therapeutics, Inc. is a precision oncology medicine company. The Company is focused on the discovery and development of small molecule, MasterKey therapies. It builds a pipeline of small molecule kinase inhibitors that target a range of driver mutations in cancer. Its technology platform, Mutation-Allostery-Pharmacology (MAP) platform is designed to allow it to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Its lead product candidate, BDTX-189, is designed as an orally available, irreversible small molecule inhibitor that targets a spectrum of 48 non-canonical and canonical driver mutations of the ErbB kinases epidermal growth factor receptor (EGFR) & HER2. BDTX-1535 is a brain-penetrant inhibitor that targets a spectrum of EGFR mutations, including allosteric and canonical mutations. It also has early-stage programs, such as B-Raf Proto-Oncogene (BRAF), and fibroblast growth factor receptor (FGFR).

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
December 29th, 2014
Public Since
January 30th, 2020
No. of Shareholders
34
No. of Employees
88
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
36,366,206

BDTX Share Price Performance

Upcoming Events for BDTX

Black Diamond Therapeutics Inc at Piper Sandler Healthcare Conference

Q4 2022 Black Diamond Therapeutics Inc Earnings Release

Q1 2023 Black Diamond Therapeutics Inc Earnings Release

Similar to BDTX

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email